Abstract #5486: Antigen displaying fluoromagnetic particles for drug assay in serum

Manuel E. Ruidíaz(La Jolla Bioengineering Institute), Bradley T. Messmer(Harvard University), Andrew C. Kummel(University of California San Diego), Thomas J. Kipps(University of California San Diego), Ana B. Sánchez(Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana)
Cancer Research
May 1, 2009
Cited by 0

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k